T. Rowe Price Associates’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-43,958
| Closed | -$3.73M | – | 2609 |
|
|
2019
Q4 | $3.73M | Sell |
43,958
-15,544
| -26% | -$1.04M | ﹤0.01% | 1454 |
|
|
2019
Q3 | $2.98M | Sell |
59,502
-1,733
| -3% | -$69.1K | ﹤0.01% | 1475 |
|
|
2019
Q2 | $2.23M | Buy |
61,235
+2,785
| +5% | +$90.9K | ﹤0.01% | 1570 |
|
|
2019
Q1 | $1.63M | Buy |
58,450
+9,000
| +18% | +$212K | ﹤0.01% | 1652 |
|
|
2018
Q4 | $946K | Sell |
49,450
-11,683
| -19% | -$272K | ﹤0.01% | 1815 |
|
|
2018
Q3 | $1.83M | Buy |
61,133
+225
| +0.4% | +$8.48K | ﹤0.01% | 1651 |
|
|
2018
Q2 | $2.23M | Sell |
60,908
-8,173
| -12% | -$266K | ﹤0.01% | 1569 |
|
|
2018
Q1 | $2.28M | Sell |
69,081
-7,645
| -10% | -$239K | ﹤0.01% | 1545 |
|
|
2017
Q4 | $2.1M | Sell |
76,726
-243,297
| -76% | -$7.49M | ﹤0.01% | 1574 |
|
|
2017
Q3 | $11.9M | Buy |
320,023
+25,502
| +9% | +$940K | ﹤0.01% | 1313 |
|
|
2017
Q2 | $11.2M | Sell |
294,521
-1,095,625
| -79% | -$48.8M | ﹤0.01% | 1302 |
|
|
2017
Q1 | $68M | Sell |
1,390,146
-58,310
| -4% | -$2.66M | 0.01% | 707 |
|
|
2016
Q4 | $49.2M | Sell |
1,448,456
-13,630
| -0.9% | -$483K | 0.01% | 814 |
|
|
2016
Q3 | $55.2M | Buy |
1,462,086
+13,586
| +0.9% | +$512K | 0.01% | 774 |
|
|
2016
Q2 | $48.7M | Buy |
1,448,500
+1,660
| +0.1% | +$58.5K | 0.01% | 793 |
|
|
2016
Q1 | $46M | Sell |
1,446,840
-10,730
| -0.7% | -$350K | 0.01% | 798 |
|
|
2015
Q4 | $54.4M | Sell |
1,457,570
-1,500
| -0.1% | -$56.7K | 0.01% | 736 |
|
|
2015
Q3 | $55.4M | Sell |
1,459,070
-2,263,035
| -61% | -$79.4M | 0.01% | 740 |
|
|
2015
Q2 | $106M | Sell |
3,722,105
-123,800
| -3% | -$3.45M | 0.02% | 583 |
|
|
2015
Q1 | $108M | Sell |
3,845,905
-42,720
| -1% | -$1.2M | 0.02% | 586 |
|
|
2014
Q4 | $108M | Buy |
3,888,625
+13,700
| +0.4% | +$339K | 0.02% | 597 |
|
|
2014
Q3 | $86.5M | Sell |
3,874,925
-7,100
| -0.2% | -$180K | 0.02% | 650 |
|
|
2014
Q2 | $113M | Sell |
3,882,025
-1,715,270
| -31% | -$45.8M | 0.02% | 602 |
|
|
2014
Q1 | $159M | Sell |
5,597,295
-244,420
| -4% | -$8.09M | 0.04% | 491 |
|
|
2013
Q4 | $226M | Sell |
5,841,715
-76,610
| -1% | -$2.74M | 0.05% | 401 |
|
|
2013
Q3 | $198M | Buy |
5,918,325
+166,230
| +3% | +$5.3M | 0.05% | 402 |
|
|
2013
Q2 | $177M | Buy |
+5,752,095
| New | +$192M | 0.05% | 421 |
|
Other funds holding MDCO
T. Rowe Price Associates's MDCO Position: Q1 2020 in Review
T. Rowe Price Associates sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 43,958 shares — an estimated $3.73M sold.
T. Rowe Price Associates first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $226M in Q4 2013. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- T. Rowe Price Associates reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- T. Rowe Price Associates sold 43,958 Medicines Co shares in Q1 2020, an estimated $3.73M.
- T. Rowe Price Associates first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- T. Rowe Price Associates's Medicines Co position peaked at $226M in Q4 2013.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.